Bonus +1: practical use of genome-wide CRISPR-Cas screen technology to identify unconventional T cell targets. Go and read this beautiful work: Crowther et al @NatImmunol 2020 https://t.co/BF6wtBlskt (2/2)
RT @HeemstraLab: Exciting work from our collaborators in the Phillips and Sewell labs! MR1 allows T-cells to selectively recognize and kill…
RT @HeemstraLab: Exciting work from our collaborators in the Phillips and Sewell labs! MR1 allows T-cells to selectively recognize and kill…
RT @HeemstraLab: Exciting work from our collaborators in the Phillips and Sewell labs! MR1 allows T-cells to selectively recognize and kill…
RT @HeemstraLab: Exciting work from our collaborators in the Phillips and Sewell labs! MR1 allows T-cells to selectively recognize and kill…
RT @HeemstraLab: Exciting work from our collaborators in the Phillips and Sewell labs! MR1 allows T-cells to selectively recognize and kill…
RT @HeemstraLab: Exciting work from our collaborators in the Phillips and Sewell labs! MR1 allows T-cells to selectively recognize and kill…
Exciting work from our collaborators in the Phillips and Sewell labs! MR1 allows T-cells to selectively recognize and kill human cancer cells! #HeemstraLabReads https://t.co/sGXfC614Qu
RT @RutterLab: Congrats to our friend and colleague John Phillips and his collaborators on their exciting new @NatImmunol paper! https://t.…
RT @RutterLab: Congrats to our friend and colleague John Phillips and his collaborators on their exciting new @NatImmunol paper! https://t.…
RT @RutterLab: Congrats to our friend and colleague John Phillips and his collaborators on their exciting new @NatImmunol paper! https://t.…
RT @RutterLab: Congrats to our friend and colleague John Phillips and his collaborators on their exciting new @NatImmunol paper! https://t.…
RT @RutterLab: Congrats to our friend and colleague John Phillips and his collaborators on their exciting new @NatImmunol paper! https://t.…
RT @RutterLab: Congrats to our friend and colleague John Phillips and his collaborators on their exciting new @NatImmunol paper! https://t.…
RT @RutterLab: Congrats to our friend and colleague John Phillips and his collaborators on their exciting new @NatImmunol paper! https://t.…
Congrats to our friend and colleague John Phillips and his collaborators on their exciting new @NatImmunol paper! https://t.co/OSXuJ0UYQS @UUtah @huntsmancancer @UofUHealth @GarryDolton @Michael44364760 @cardiffuni @MonashUni #TCR #MHC #cancer #MR1
Check out this brand new Nature article on a new CAR-T cell targeting receptor MR1 which promises ubiquitous T Cell cancer targeting for both solid and blood borne cancers! https://t.co/tj9G9spPvL
Check out new work from my colleague in Utah. https://t.co/s0HhJIUwCD @UofUtahCIHD
Enjoy reading this paper very much!The screening system for cargo bound MR1 is elegant and a pan-target for T cell therapy...would be the opposite of CarT. Cannot be more promising.
RT @UofUtahCIHD: Newly published! Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC cl…
#WorldCancerDay2020 Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1 | Nature Immunology https://t.co/U1oZCGmU9G
RT @UofUtahCIHD: Newly published! Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC cl…
Newly published! Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1 https://t.co/4J8DMyKygX #CRISPR #AcademicTwitter #sciencetwitter #research #researchpapers #researchers #
RT @alephh: "T-cell receptor (TCR) MC.7.G5 recognizes diverse cancer cell types whatever HLA (Human leukocyte antigen) is➡️pan-cancer genom…
Probably the best news we can get in 2020. New type of immune cell (t-cell) found @cardiffuni which can fight with different types of cancer (MR1). If things go well human trials will start as soon as November. Article https://t.co/ZEnNtj3l49 Report ht
Everyone check out this article that my dad is published in! His help in an immune discovery could treat ALL CANCER!! https://t.co/JjhwcnQMsP
Check out this brand new Nature article on a new CAR-T cell targeting receptor MR1 which promises ubiquitous T Cell cancer targeting for both solid and blood borne cancers! https://t.co/bPbOfP4WQp
RT @hus_qy: 3\ ... for curing cancer and human trials in terminally ill patients could start as early as this year. This is a really big b…
This discovery will enable T-cell based cancer therapies to be effective against a considerably broader patient population! https://t.co/JZBcCLipoJ
Check out this brand new Nature article on a new CAR-T cell targeting receptor MR1 which promises ubiquitous T Cell cancer targeting for both solid and blood borne cancers! https://t.co/pS3e4A40i5
RT @NatureBiotech: A human T cell receptor directs tumor cell killing via recognition of MR1 and cancer cell-derived metabolites https://t.…
Check out this brand new Nature article on a new CAR-T cell targeting receptor MR1 which promises ubiquitous T Cell cancer targeting for both solid and blood borne cancers! https://t.co/hcdEJNJYDG
Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1. Nat Immunol #metabolomics https://t.co/m8cEeRS6yk
RT @toxiven_biotech: For further information go to link: https://t.co/RR06exxvIT
RT @davidasinclair: Wow! Immune cells found to target a cancer-ubiquitous protein called MR1 that recognizes vitamin B2 derivatives. Could…
Scientists at @cardiffuni discovered a #TCell and its receptor that could find and destroy many types of cancerous cells including lung, skin, blood, colon, breast, bone, prostate, ovarian, kidney and cervical while leaving healthy cells untouched! https:
RT @davidasinclair: Wow! Immune cells found to target a cancer-ubiquitous protein called MR1 that recognizes vitamin B2 derivatives. Could…
New Immune Cell That Could Kill Most Cancers Discovered By Accident During Research https://t.co/dzSiZFVgi2
@SciencePost_fr [L’étude à découvrir] 20/01 > Le criblage #CRISPR - Cas9 à l'échelle du génome révélé un ciblage omniprésent du cancer des cellules T via la protéine MR1 monomorphe lié au CMH de classe I https://t.co/lXEolGNPZR via @nature #LaMethSci
RT @davidasinclair: Wow! Immune cells found to target a cancer-ubiquitous protein called MR1 that recognizes vitamin B2 derivatives. Could…
The MR1 https://t.co/XMRvhNkHpj and now this, looks like signalling is the most promising way to move forward?Adenosine signalling is prognostic for cancer outcome and has predictive utility for immunotherapeutic response https://t.co/9ijyvhHVKt
RT @NatImmunol: Sewell and colleagues show nonclassical MHC molecule MR1 is expressed on a wide variety of cancer types and can be targeted…
.@cardiffuni researchers have identified a T-cell receptor that targets most human cancer cell types while remaining inert to non-cancerous cells. https://t.co/ovJPvRqhWi @NatImmunol https://t.co/TdWTA2Lxc6
It's great to see our community further tapping into the potential of metabolomics 💫 Whether this rising field will play a significant role in advancing cancer treatment and diagnosis is a question of when, rather than if.
Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1 https://t.co/Pj1aY7fkXa
RT @CaptainTCell: Amazing work from @Michael44364760 and Andrew Sewell’ lab. Describing a #TCR recognizing and killing most human #cancer t…
RT @SirtSix: @JSheltzer Seems like the recent M1R paper suggests that some metabolic determinants may exist. Even if we don't know what the…
RT @sm_vol: I thought I had just learned that MR1 could be part of the answer to fight cancer (https://t.co/GWYsEwWFYH)...but it seems that…
I thought I had just learned that MR1 could be part of the answer to fight cancer (https://t.co/GWYsEwWFYH)...but it seems that it's also part of the problem!
Amazing work from @Michael44364760 and Andrew Sewell’ lab. Describing a #TCR recognizing and killing most human #cancer types via the monomorphic #MHC class I-related protein #MR1. A big step in cancer treatments! @cardiffuni #CRISPR #CAS9 https://t.co/Aj0
RT @ChudakovM: https://t.co/qwRbiiyhm5 Admiration, envy, hope, inspiration ... altogether. And love for Andrew Sewell and his way of think…
RT @ShorterLab: Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protei…
https://t.co/qwRbiiyhm5 Admiration, envy, hope, inspiration ... altogether. And love for Andrew Sewell and his way of thinking. Ultimately - inspiration.
"Here, we use genome-wide CRISPR–Cas9 screening to establish that a T cell receptor (TCR) recognized and killed most human cancer types via the monomorphic MHC class I-related protein, MR1, while remaining inert to noncancerous cells." That's incredible.
Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1 #CRISPR #Cancer #Tcells https://t.co/w6pZcROvWH
إنَّ العلاج بالخلايا المناعيّة المعدلة جينيًا ليس بالتقنية الجديدة، فهو موجود ومطبق من قبل، إلا أنَّه لم يكن فعالاً بالقضاء على الأورام الصلبة التي تسبب أغلب أنواع السرطانات، إذ كان يعالج سرطانات الدم فقط. المصادر: 1- https://t.co/O43v2kjmUS 2- https://
Oh yes! That one.. Cell culture & mice experiments..Great finding..but in-human use..let's wait for more papers..
@manjuggm Did you also have the last @nature ubiquitous cancer-targeting T-cell paper keep you busy for days?!! Great paper but the news reporting was all over the place!!! https://t.co/MOZUGCaXLh
RT @Andres_Lopez_C: 🧬 Se descubre un nuevo tipo de ‘killer T-cell’ equipado con un nuevo tipo de receptor capaz de reconocer y matar la may…
RT @Andres_Lopez_C: 🧬 Se descubre un nuevo tipo de ‘killer T-cell’ equipado con un nuevo tipo de receptor capaz de reconocer y matar la may…
RT @rewireDE: Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein…
Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1 https://t.co/clpF9NDcqu
RT @davidasinclair: Wow! Immune cells found to target a cancer-ubiquitous protein called MR1 that recognizes vitamin B2 derivatives. Could…
RT @bidatzi: BOOM, this one's a home run: Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic…
Pan-cancer, pan-population immunotherapy? https://t.co/xoU9l12MHJ
RT @gabyrabi: Un estudio revela la existencia de linfocitos T anti tumorales universales que eliminan varios tipos de tumores que expresan…
RT @NatImmunol: Sewell and colleagues show nonclassical MHC molecule MR1 is expressed on a wide variety of cancer types and can be targeted…
RT @charlesgraeber: Good eye @KeeganLarson @nature - "These findings offer opportunities for HLA-independent, pan-cancer, pan-population im…
RT @NatImmunol: Sewell and colleagues show nonclassical MHC molecule MR1 is expressed on a wide variety of cancer types and can be targeted…
🔬 Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1. 📝 Nat Immunol. 👨🏻🔬 Crowther MD, et al. 🌎 https://t.co/bQjfuty3oL #science #research https://t.co/w8WLgzUJkw
@notibomba Estudio original: https://t.co/vNiS2xEZJw
This decade we will kill cancer! Maybe the best new! https://t.co/3H11ubRDlt
Just finished reading The Breakthrough by @charlesgraeber so this was super exciting to see! https://t.co/tQkMJag6Ra
🔬 Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1. 📝 Nat Immunol. 👨🏻🔬 Crowther MD, et al. 🌎 https://t.co/bQjfuty3oL #science #research https://t.co/nZibXp4E86
RT @hus_qy: 3\ ... for curing cancer and human trials in terminally ill patients could start as early as this year. This is a really big b…
So cool if this pans out: new type of T-cell discovered that allows treatment of all #cancer types! #CancerResearch https://t.co/Bxuc8W3PTa
@ErvaxxLtd pursues non-peptide tumor antigens via Cardiff University TCR, T-cell deal @BioCentury including exciting new findings published in @NatImmunol https://t.co/vaTcxWlsk6 https://t.co/owD6R7v4yn
Discovery of new T-cell raises prospect of 'universal' cancer therapy: https://t.co/317v7M9o2J https://t.co/NGVAvzyB79
これ読もうと思ったのに忘れてて帰って来ちゃった。明日読む時間あるかな。 https://t.co/jcmy5Zy2La
RT @NatImmunol: Sewell and colleagues show nonclassical MHC molecule MR1 is expressed on a wide variety of cancer types and can be targeted…
RT @davidasinclair: Wow! Immune cells found to target a cancer-ubiquitous protein called MR1 that recognizes vitamin B2 derivatives. Could…
@cardiffuni והמאמר עצמו: https://t.co/l4cAwombJB
RT @akdes: Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1…
L'article en accès libre https://t.co/IMSsPLUkWq
Je sais que tous les 6 mois on croit avoir trouvé un remède contre le cancer, mais là pour une fois, cette perspective d'immunothérapie semble particulièrement prometteuse https://t.co/LSu7wispie
Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1: https://t.co/q7ZXrhnMTi
RT @hus_qy: 3\ ... for curing cancer and human trials in terminally ill patients could start as early as this year. This is a really big b…
Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1 | Nature Immunology https://t.co/XIyX48uCZJ
@AylinERK https://t.co/98PqoC6O4V ilgili makale burda. Bahsi geçen şey sadece popüler bir haber henüz ..
Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1 https://t.co/aCGrOiUqMo
RT @davidasinclair: Wow! Immune cells found to target a cancer-ubiquitous protein called MR1 that recognizes vitamin B2 derivatives. Could…
RT @NatImmunol: Sewell and colleagues show nonclassical MHC molecule MR1 is expressed on a wide variety of cancer types and can be targeted…
New work on T-cell therapies, which can be used to treat all types of cancers. Its like "One-size-fits-all" cancer therapy.. #CRISPR, #Cancer_therapy, #One_size_fits_all https://t.co/2qbLXY90oC